PIPGEN - PhD Project 2: Understanding the physiopathology of PROS.
Research · Université de Paris > France
RESEARCH PROFILE: First Stage Researcher (R1)
APPLICATION DEADLINE: 27 June 2021
EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020
MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 955534
 First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.
PhD Project details
A challenging issue is the broad clinical presentation of PROS patients. To favour the inclusion of patients in potential clinical trials, stratification is mandatory. Based on our clinical expertise, we intend to classify patients according to the tissue layers that are involved in the malformation. To better understand the different subgroup of patient phenotypes, we have generated mouse models expressing oncogenic PIK3CA in specific tissues (including adipose, osteoblast, lymphatic, endothelial cells, muscle, Schwann cells). With a specific focus on veins and lymphatic vessels, ESR2 will express PIK3CAmut in genetically modified mouse models, followed by characterising their macroscopy phenotype, scRNAseq, and culture of lesion-derived cells.
Host: Université de Paris, France.
Supervisor: Prof Guillaume Canaud.
Doctoral programme: Université de Paris.
Envisioned secondments: KITHER, UCL.
The selected candidate will have to undergo a second row of application in order to formally be admitted and allowed to enrol in the Université de Paris.